8-K

    UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 18, 2012

AEMETIS, INC.

(Exact name of registrant as specified in its charter)

______________

Nevada	000-51354	26-1407544
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

20400 Stevens Creek Blvd., Suite 700

Cupertino, California 95014

(Address of Principal Executive Office) (Zip Code)

 (408) 213-0940

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

The Company issued a press release announcing that it will hold a business update conference call for interested shareholders, at 1:15 PM, Pacific Daylight Time on December 20, 2012.  A copy of the presentation the Company plans to make on the conference call will be available on the Company’s website prior to the start of the call and is incorporated by reference into this Item 7.01.

The information contained herein and the attached exhibit is furnished to, but for purposes of Section 18 of the Securities Exchange Act of 1934 shall not be deemed filed with, the Securities and Exchange Commission. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated therein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated December 18, 2012

2

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	AE Biofuels, Inc.
Date:  December 18, 2012	By:	/s/  Eric A. McAfee
		Eric McAfee
		Chief Executive Officer

3

EX-99.1

EXHIBIT 99.1

Media Contact:	Investor Relations:	Investor & Analyst Contact:
Andy Foster	Michael Bayes	Todd Waltz
(408) 213-0928	Liviakis Financial	(408) 213-0925
afoster@aemetis.com	(415) 389-4670	twaltz@aemetis.com

Aemetis To Hold Shareholder Update Call at 1:15 p.m. PDT on December 20, 2012

CUPERTINO, Calif. – December 18, 2012 – Aemetis, Inc. (OTCPK: AMTX), an advanced fuels and renewable chemical company, announced today that the company will host a business update conference call at 1:15 PM, Pacific Daylight Time on December 20, 2012.

Shareholders may submit questions to management prior to Noon Pacific Daylight Time on December 19, 2012 using the following email address:  john@liviakis.com.

Date: December 20, 2012

Time: 1:15 PM PT

Dial-in: (559) 726-1300

Access code: 166576

If you are unable to listen to the call on the 20th of December, the webcast will be archived on the Company’s website (www.aemetis.com).  The voice recording will also be available for 90 days by dialing (559) 726-1399, access code 166576.

About Aemetis

Headquartered in Cupertino, California, Aemetis is an advanced fuels and renewable chemicals company.  Aemetis owns and operates a 55 million gallon renewable fuels plant in California; and owns and operates a 50 million gallon capacity renewable chemicals and advanced fuels production facility on the east coast of India.  Aemetis operates a research and development laboratory at the Maryland Biotech Center, and holds four granted patents and ten pending patents on its Z-microbe and related technology for the production of renewable fuels and chemicals.  For additional information about Aemetis, please visit www.aemetis.com.

###